It is great to have an opportunity to collaborate with the research teams from all of the study centers.
Alachua, FL (PRWEB) September 10, 2015
AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the presentation of data on AxoGen’s Avance® Nerve Graft, including data from the RANGER® Registry, at the 70th Annual Meeting of the American Society for Surgery of the Hand (ASSH), taking place September 10-12, 2015 in Seattle, Washington.
Today, during the best clinical papers feature of the conference, Dr. Gregory Buncke, Director of The Buncke Clinic in San Francisco, will present "Evaluating Nerve Repair Outcomes in Upper Extremity Nerve Injuries Utilizing Processed Nerve Allografts, Tube Conduits, and Nerve Autograft". The outcomes are from an expanded data set from the RANGER® Study, a multicenter observational registry in peripheral nerve repair, and include outcomes on the use of Avance® Nerve Graft across a range of nerve injuries in the hand and upper extremity. "It is great to have an opportunity to collaborate with the research teams from all of the study centers,” stated Dr. Buncke. “Data from this program has already begun to aid surgeons in their clinical decision making. We are very enthusiastic about our current findings and the continued expansion of the RANGER Study”.
“There is great interest from the surgical community in advancing the understanding of peripheral nerve repair algorithms and RANGER® has become a landmark program in peripheral nerve repair,” commented Erick DeVinney, Vice President of Clinical and Translational Sciences at AxoGen. We are honored to partner with the Clinical Investigators who support and drive this program and we are pleased to see this acknowledgment of their efforts and of the importance of this research”.
About the RANGER® Study
The RANGER® Study, A Multicenter Retrospective Study of Avance® Nerve Graft Utilization Evaluations and Outcomes in Peripheral Nerve Injury Repair is an active, multicenter clinical database with 18 contributing centers designed to continuously monitor and collect injury, repair, safety and outcomes data for peripheral nerve injuries repaired with processed nerve allograft (Avance® Nerve Graft), nerve autograft and synthetic tubes. As of May 2015, the study included more than 650 nerve repairs enrolled across 18 centers and 40 surgeons. The RANGER® Study is an AxoGen sponsored ongoing open label registry study. Each patient outcome is dependent upon the nature and extent of nerve loss or damage, timing between nerve loss and repair and the natural course of the patient’s recovery. Results presented at the ASSH meeting may not represent typical clinical outcomes for individual patients.
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.
For more information about AxoGen or to sign up for our news alerts, please visit http://www.AxoGenInc.com.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our 2015 revenue estimate, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Gregory Freitag, Chief Financial Officer & General Counsel
Michael Polyviou/Doug Sherk – Investor Relations